Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
122 Results for "
IBDs
" in MedChemExpress (MCE) Product Catalog:
Products (122)
122 Results for "IBDs" in MCE Product Catalog:
Cat. No.: HY-P11039
Target:
Research Areas:
Cat. No.: HY-P991552
Target:
Research Areas:
Cat. No.: HY-171592
CAS No.: 2789711-40-4
Research Areas:
RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM). RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα). RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD) .
Cat. No.: HY-P11214
CAS No.: 2243975-43-9
Synonyms: H-TL1
Research Areas:
Cat. No.: HY-176535
CAS No.: 2648377-08-4
Synonyms: BBC0115
Research Areas:
KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with Kd values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.
Cat. No.: HY-14908A
CAS No.: 1354012-90-0
Synonyms: 4sc-101 hemicalcium; SC12267 hemicalcium
Research Areas:
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .
Cat. No.: HY-16151
CAS No.: 457939-22-9
Target:
Research Areas:
CR-3294 is an autophagy inducer in hypoxic cells. CR-3294 is an inducible enzyme nitric oxide synthase (iNOS) inhibitor. CR-3294 inhibits both the DNA binding of HIF-1alpha and VEGF mRNA synthesis. CR-3294 can be used for the study of breast cancer and inflammatory bowel disease (IBD), such as Crohn’s disease, ulcerative colitis .
Cat. No.: HY-171591
CAS No.: 2810810-00-3
Research Areas:
SIK2-IN-4 (Compound 4) is a highly selective SIK1/2 inhibitor (IC50s 0.143 and 0.076 μM, respectively). SIK2-IN-4 reduces the phosphorylation of transcription coactivator 3 (CRTC3) by targeting SIK1/2, thereby regulating cAMP response element binding protein (CREB)-dependent transcriptional activity. SIK2-IN-4 inhibits the production of pro-inflammatory cytokines such as TNF (IC50: 0.11 µM), IL-12/23 p40 (IC50: 0.25 µM), and IL-23 (IC50: 0.47 µM), while inducing the expression of the anti-inflammatory cytokine IL-10. SIK2-IN-4 can be used to study intestinal inflammation and other chronic inflammatory diseases .
Cat. No.: HY-161620
CAS No.: 2626988-87-0
Target:
Research Areas:
DW18134 is an inhibitor for interleukin receptor-associated kinase 4 (IRAK 4) with an IC50 of 11.2 nM. DW18134 inhibits phosphorylation of IRAK4 and IKK, downregulates the secretion of TNF-α and IL-6. DW18134 attenuates the Lipopolysaccharides (HY-D1056)-induced peritonitis and DSS-induced colitis in mouse models, and protects the intestinal barrier function .
Cat. No.: HY-12820R
CAS No.: 1616113-45-1
Synonyms: Antibiotic-202 (Standard)
Target:
Research Areas:
Sibofimloc (Standard) is the analytical standard of Sibofimloc. This product is intended for research and analytical applications. Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD)[1][2].
Cat. No.: HY-118795
CAS No.: 262451-89-8
Target:
Research Areas:
SC-22716 is a potent, competitive, reversible inhibitor of human LTA4 hydrolase, with an IC50 of 0.20 µM. SC-22716 has potential for the research of inflammatory bowel disease (IBD) and psoriasis .
Cat. No.: HY-155199
CAS No.: 2982945-34-4
Target:
Research Areas:
PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor (IC50: 15 nM). PDE1-IN-5 has anti- inflammatory activity, and inhibits expression of iNOS, TNF-α, IL-1α, IL-1β, and IL-6 induced by LPS. PDE1-IN-5 has anti-inflammatory bowel disease (IBD) effects in the dextran sodium sulfate (DSS)-Induced colitis mice model. PDE1-IN-5 can be used for research of IBD .
Cat. No.: HY-155680
CAS No.: 2677039-24-4
Target:
Research Areas:
BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC50=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research .
Cat. No.: HY-P10966
Research Areas:
Cat. No.: HY-B0174AR
CAS No.: 15722-48-2
Target:
Research Areas:
Olsalazine (Standard) is an orally active prodrug of 5-ASA (HY-15027). Olsalazine (Standard) can inhibit cells proliferation and induce apoptosis. Olsalazine (Standard) can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine (Standard) can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
Target:
Research Areas:
Olsalazine Disodium (Standard) is an orally active prodrug of 5-ASA (HY-15027). Olsalazine Disodium (Standard) can inhibit cells proliferation and induce apoptosis. Olsalazine Disodium (Standard) can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine Disodium (Standard) can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
Cat. No.: HY-173180
Research Areas:
5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory activity. 5-LOX-IN-8 suppresses IL-6, IL-1β, TNF-α and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. 5-LOX-IN-8 reduces disease activity in a DSS colitis model. 5-LOX-IN-8 can be used for research of inflammatory bowel disease (IBD) .
Cat. No.: HY-176273
Target:
Research Areas:
RORγt inverse agonist 35 (Compound 22) is a RORγt inverse agonist with an IC50 of 1.51 μM. RORγt inverse agonist 35 significantly inhibits Th17 differentiation and proinflammatory properties in human CD4 + T cells. RORγt inverse agonist 35 can be used for research of Th17-driven autoimmune diseases, such as psoriasis, multiple sclerosis, and inflammatory bowel disease (IBD) .
Cat. No.: HY-170218
Research Areas:
NLRP3-IN-76 is an orally active NLRP3 inhibitor. NLRP3-IN-76 inhibits the production of NO, and the mRNA levels of proinflammatory cytokines (iNOS, IL-6, IL-1β and TNFα). NLRP3-IN-76 shows anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and NF-κB signaling pathway. NLRP3-IN-76 ameliorates DSS (HY-116282C)-induced colitis and can be used for research of inflammatory bowel diseases (IBD) .
Cat. No.: HY-174287
CAS No.: 3066895-41-5
Target:
Research Areas:
Keap1-IN-2 (Compound 164) is a KEAP1 inhibitor (IC50: 2 nM). Keap1-IN-2 indirectly activates Nrf2 by inhibiting KEAP1, thereby enhancing the antioxidant capacity of cells. Keap1-IN-2 promotes the accumulation and nuclear translocation of Nrf2 by blocking KEAP1-mediated Nrf2 degradation. Keap1-IN-2 can be used to study diseases associated with oxidative stress, such as inflammatory bowel disease, Crohn's disease, and immune diseases such as ulcerative colitis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
